期刊
BIOMEDICINES
卷 9, 期 5, 页码 -出版社
MDPI
DOI: 10.3390/biomedicines9050573
关键词
painful diabetic neuropathy; diabetes; neuropathic pain; peripheral diabetic neuropathy; neuromodulation; 10 kHz SCS; spinal cord stimulation
Painful diabetic neuropathy (PDN) is a common complication of diabetes mellitus that significantly impacts quality of life. Various pharmacological options such as anticonvulsants, antidepressants, and topical capsaicin, as well as the recently approved tapentadol, are recommended for managing PDN. In addition to pharmacotherapy, neuromodulation therapies such as intrathecal therapy, TENS, and SCS have shown success in providing pain relief for PDN patients.
Painful diabetic neuropathy (PDN) is a common complication of diabetes mellitus that is associated with a significant decline in quality of life. Like other painful neuropathic conditions, PDN is difficult to manage clinically, and a variety of pharmacological and non-pharmacological options are available for this condition. Recommended pharmacotherapies include anticonvulsive agents, antidepressant drugs, and topical capsaicin; and tapentadol, which combines opioid agonism and norepinephrine reuptake inhibition, has also recently been approved for use. Additionally, several neuromodulation therapies have been successfully used for pain relief in PDN, including intrathecal therapy, transcutaneous electrical nerve stimulation (TENS), and spinal cord stimulation (SCS). Recently, 10 kHz SCS has been shown to provide clinically meaningful pain relief for patients refractory to conventional medical management, with a subset of patients demonstrating improvement in neurological function. This literature review is intended to discuss the dosage and prospective data associated with pain management therapies for PDN.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据